SCYNEXIS, Inc. (NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET
Company Participants
Debbie Etchison - Communications & IR
Dr. Marco Taglietti - President & CEO
Dr. David Angulo - Chief Medical Officer
Ivor Macleod - Chief Financial Officer
Conference Call Participants
Louise Chen - Cantor
Michael Higgins - Ladenburg Thalmann
Shubhendu Sen Roy - Brookline Capital Markets
Operator
Good morning, and welcome to the SCYNEXIS Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
I would now like to turn the conference over to Debbie Etchison, Executive Director, Communications and Investor Relations.
Debbie Etchison
Hello, everyone, and welcome to today's conference call to discuss our third quarter 2022 financial results and corporate update. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, leadership's expectations for our future financial and operational performance, as well as our business strategy because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
Please refer to our filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q, including in each case under the caption Risk Factors and another documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements speak only as of today, November 9th, 2022. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
The information on today's call is not intended for promotional purposes and not sufficient for prescribing decisions.
Joining us on today's call are SCYNEXIS' President and CEO, Marco Taglietti; Chief Medical Officer, Dr. David Angulo; and Chief Financial Officer, Ivor Macleod. Following our prepared remarks, we'll open the call to your questions.
Now, I will turn the call over to Dr. Marco Taglietti, President and CEO.
Dr. Marco Taglietti
Thank you, Debbie. Good morning, everyone. Bonjour [indiscernible]. Thank you for joining us today for our third quarter 2022 earnings investor call. I want to begin by drawing your attention to a recent report issued by the World Health Organization or WHO. This was the first ever list of priority deadly fungal pathogens that are becoming a growing, global public health manage.